Company Filing History:
10 out of 1,271 
2 out of 2 
1 out of 18 Years Active: 2010-2021
Title: David Clemmons: Innovator in Metabolic and Bone Disorder Treatments
Introduction: David Clemmons, an esteemed inventor based in Chapel Hill, North Carolina, is renowned for his significant contributions to medical science. With a remarkable portfolio of 12 patents, he has played a pivotal role in advancing treatments for metabolic and bone disorders.
Latest Patents: Among his most recent innovations, Clemmons has developed groundbreaking technologies. One of his notable patents pertains to the heparin-binding domain of insulin-like growth factor binding protein-2 (IGFBP-2). This technology focuses on the modulation of metabolic disorders through specific compounds and peptides. In another significant development, Clemmons has introduced peptides derived from IGFBP-2 aimed at improving bone disorders. Both patents highlight his commitment to enhancing therapeutic strategies and improving patient outcomes.
Career Highlights: Throughout his career, David Clemmons has been affiliated with prestigious organizations, including the University of North Carolina at Chapel Hill and Amolyt Pharma. His tenure at these institutions has allowed him to contribute meaningfully to research and innovation in the biomedical field.
Collaborations: Clemmons has collaborated with esteemed colleagues such as Laura A. Maile and Michael Naso, fostering a collaborative environment that enhances the quality and impact of their joint research endeavors.
Conclusion: David Clemmons is a distinguished inventor whose work has made a significant impact in the field of medicine, particularly in treating metabolic and bone disorders. His extensive patent portfolio and collaborations with notable professionals underscore his dedication to innovation and improving healthcare solutions.